Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 1/20 | 0.59 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.59 |
| ▸ | PARG | Q86W56 | 7/20 | 0.55 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | HPD | P32754 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6241073 | 0.89 | MMP13 (0.71) | MMP13SLC22A8PARGHDAC1KDM4E | |
| SCHEMBL6432931 | 0.88 | MMP13 (0.55) | MMP13SLC22A8PARGHDAC1KDM4E | |
| SCHEMBL7097504 | 0.87 | PARG (0.57) | MMP13SLC22A8PARGHDAC1CNR2 | |
| SCHEMBL6253605 | 0.87 | MMP13 (0.62) | MMP13SLC22A8PARGHDAC1KDM4E | |
| SCHEMBL7100616 | 0.87 | MMP13 (0.62) | MMP13SLC22A8PARGTBXAS1HDAC1 | |
| SCHEMBL7095893 | 0.86 | MMP13 (0.61) | MMP13SLC22A8PARGTBXAS1HDAC1 | |
| SCHEMBL6238935 | 0.86 | MMP13 (0.61) | MMP13SLC22A8PARGHDAC1KDM4E | |
| SCHEMBL6256249 | 0.86 | MMP13 (0.61) | MMP13SLC22A8PARGHDAC1KDM4E | |
| SCHEMBL6241901 | 0.84 | CNR2 (0.56) | MMP13SLC22A8PARGHDAC1HPD | |
| SCHEMBL7019308 | 0.84 | MMP13 (0.59) | MMP13SLC22A8PARGHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1368324-A1 | QUINAZOLINES AS MMP-13 INHIBITORS | Warner-Lambert Company LLC (US) | 2003-12-10 | — | — | EP | disclosed |
| US-20020193377-A1 | Quinazolines as MMP-13 inhibitors | ANDRIANJARA CHARLES (FR) | 2002-12-19 | — | — | US | disclosed |
| WO-2002064572-A1 | QUINAZOLINES AS MMP-13 INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193377-A1 | Quinazolines as MMP-13 inhibitors | MMP13, MMP9, MMP3 | MMP13 1/4885SLC22A8 315/4885PARG 3624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.